Robin Carhart-Harris, PhD, is a British psychologist and neuroscientist researching psychedelics and their efficacy in the treatment of major depression.
CLEAR ALL
Robin has been conducting pioneering brain imaging studies of psychedelic drugs. Most recently, he has completed the first phase of a clinical trial looking at the potential of psilocybin to treat depression, and his talk looks at how these drugs can be used in treatment.
Research into psychedelics, shut down for decades, is now yielding exciting results.
How magic mushrooms expand consciousness.
In a recent UK trial, 12 patients with major depression took a pill quite different to commonly prescribed antidepressants: 25mg of psilocybin, the psychedelic compound found in magic mushrooms.
Dr Robin Carhart-Harris talks about his scientific research into the effects and potential therapeutic uses of psychedelic drugs. Join him as he discusses brain imaging work involving psilocybin, the active ingredient of magic mushrooms, and explains how the drug works in the brain.
Near-death experiences (NDEs) are complex subjective experiences, which have been previously associated with the psychedelic experience and more specifically with the experience induced by the potent serotonergic, N,N-Dimethyltryptamine (DMT).
How could LSD and psilocybin help with mental health, palliative care and addictive behaviours? What was the point of a psilocybin mushroom evolving the way that it did? Michael Pollan explores the “second wave” of international research and discusses what psychedelic drugs may teach us about th...
The scientists hope their long-awaited study on LSD in humans will open the floodgates to further research into psychedelics.
Abstract: Highlighting the results of two fMRI studies and one MEG study with psilocybin and an fMRI study with MDMA, Carhart-Harris will report the effects of both drugs on regional brain activity and brain network organization.
Photo Credit: Photograph by Thomas Angus, Imperial College London / Distributed under the CC BY-SA 4.0
